

SMO protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/S966E6CF1162EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: S966E6CF1162EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "SMO protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in SMO protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

SMO protein inhibitors Understanding

SMO protein inhibitors: Overview

SMO is a G-protein-coupled receptor (GPCR) of the Frizzled-class (class-F). It transduces the Hedgehog signal from the tumour suppressor Patched-1 (PTCH1) to the glioma-associated-oncogene (GLI) transcription factors, which activates the Hedgehog signalling pathway. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma. Overexpression of either Wnt-1 or the GLI proteins results in cancer. Inhibition of the Smoothed (SMO) protein prevents the induction of GLI transcriptional activity upon exposure of cancer cells to Shh ligands. Loss of induction of GLIs upon activation of Shh signaling inhibits the ability of Shh signaling to promote tumor progression. Therapies that inhibit Smo have many

applications in cancer treatment, therefore several active clinical trials are going on to check efficacy.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence SMO protein inhibitors R&D. The therapies under development are focused on novel approaches for SMO protein inhibitors.

SMO protein inhibitors Emerging Drugs Chapters

This segment of the SMO protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

SMO protein inhibitors Emerging Drugs

GT1708F: Suzhou Kintor Pharmaceuticals

GT 1708F is a smoothened trans-membrane protein (SMO) antagonist (or Hedgehog signaling pathway inhibitor). The drug is currently in Phase I clinical studies for the treatment of leukemia and Basal Cell Carcinoma.

ENV-101: Endeavor BioMedicines

ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog signaling pathway that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor intends to initiate a Phase 2 study of ENV-101 as a monotherapy in patients with IPF in the second quarter of 2021.

Further product details are provided in the report.....

SMO protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different SMO protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on SMO protein inhibitors

There are approx. 8+ key companies which are developing the SMO protein inhibitors. The companies which have their SMO protein inhibitors drug candidates in the most advanced stage, i.e. Phase III, PellePharm.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

SMO protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

SMO protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses SMO protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging SMO protein inhibitors drugs.

SMO protein inhibitors Report Insights

SMO protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

SMO protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing SMO protein inhibitors drugs?

How many SMO protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for SMO protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the SMO protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for SMO protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Endeavor BioMedicines

PellePharm

Sun Pharmaceutical Industries

Roche

Guangdong Zhongsheng Pharmaceutical

Suzhou Kintor Pharmaceuticals

Key Products

Glasdegib

ENV-101

Patidegib

Sonidegib

Vismodegib

ZSP1602

GT1708F

Contents

Introduction

Executive Summary

SMO protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

SMO protein inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

SMO protein inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

SMO protein inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Patidegib: PellePharm

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II/III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

ENV-101: Endeavor BioMedicines

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

SMO protein inhibitors Key Companies

SMO protein inhibitors Key Products

SMO protein inhibitors- Unmet Needs

SMO protein inhibitors- Market Drivers and Barriers

SMO protein inhibitors- Future Perspectives and Conclusion

SMO protein inhibitors Analyst Views

SMO protein inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for SMO protein inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for SMO protein inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: SMO protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/S966E6CF1162EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S966E6CF1162EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970